Latest news
Gilead Sciences Raises 2026 Outlook Following Q2 Revenue Beat - sekbernews.idsekbernews.id · Sat, 08 Aug 2026 14:47:25 GMTGilead’s HIV PrEP franchise hits $1B quarterly sales, but analysts question Yeztugo durability - Fierce PharmaFierce Pharma · Wed, 05 Aug 2026 14:44:51 GMTGilead’s Yeztugo beats forecasts as HIV PrEP franchise exceeds $1B - Endpoints NewsEndpoints News · Wed, 05 Aug 2026 01:21:00 GMTGilead Sciences (NASDAQ:GILD) Issues Earnings Results, Beats Estimates By $0.51 EPS - MarketBeatMarketBeat · Wed, 05 Aug 2026 00:14:20 GMTGilead second-quarter sales rise 8%, beating Wall Street estimates - ReutersReuters · Tue, 04 Aug 2026 22:26:25 GMTGilead Sciences (NASDAQ:GILD) Beats Expectations in Strong Q2 CY2026 - StockStoryStockStory · Tue, 04 Aug 2026 21:42:46 GMTGilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates - Yahoo FinanceYahoo Finance · Tue, 04 Aug 2026 21:15:02 GMTOpinion | Gilead Beats the Plaintiff Bar - WSJWSJ · Sun, 02 Aug 2026 07:00:00 GMT